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Summary.  Prodigiosin (PG) is a red pigment produced
by Serratia marcescens with immunosuppressive and
apoptotic activities. In this study, we sought to examine
the effect of PG on cell cycle-related proteins. The
antiproliferative activity of PG was tested using human
Jurkat leukaemia T cells in culture. PG-inhibited cell
proliferation was determined using thymidine
incorporation assay. PG-arrested cell cycle was analysed
using immunoblot analysis with specific antibodies
against cell cycle-related proteins and kinase assays of
cdk2. Apoptosis was determined by Hoechst staining
and analysis of DNA fragmentation. PG inhibited cyclin
E, cdk2, p27 and p21, the induction of the cyclin A-cdk2
and cyclin E-cdk2 kinase activity, and the
phosphorylation of Rb in leukaemic Jurkat cells. We
confirmed that PG induces apoptosis by the
characteristic DNA laddering pattern and condensed
nuclei or apoptotic bodies identified by fluorescence
microscopy. These results indicate that PG and other
family members form a new group of molecules with a
common mechanism of action and specific molecular
targets, raising the possibility of their therapeutic use as
antineoplastic drugs.
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Introduction
In the search for new anticancer drugs several
bacterial pathogens have been identified as mediators of
apoptosis in vitro and during pathogenesis (Zychlinsky
and Santonetti, 1997). Bacterial toxins like leukotoxin,
α-toxin and haemolysin form pores in the eukaryotic cell
membrane and disrupt the cell via osmotic swelling
(Hildebrand et al., 1991; Mangan et al., 1991; Jonas et
al., 1993). Other toxins like diphtheria toxin and
exotoxin A inhibit protein synthesis, causing apoptosis
in eukaryotic cells (Morimoto and Bonavida, 1992;
Kochi and Collier, 1993).
A family of natural red pigments called prodigiosins
are synthesised by bacteria. Prodigiosin 25-C
(undecylprodigiosin, UP) and cycloprodigiosin
hydrochloride (cPrG•HCl) are synthesised by
Streptomyces spp and Pseudoalteromonas denitrificans,
respectively, and they have immunosuppressive and
apoptotic qualities (Tsuji et al., 1992; Kawauchi et al.,
1997; Songia et al., 1997; Azuma et al., 2000; Lee et al.,
2000; Yamamoto et al., 2000a). UP inhibits proliferation
of both T and B human lymphocytes but not
proliferation of transformed leukaemic cell lines (Songia
et al., 1997). Very recently, screening for anticancer
agents in vitro in our laboratory led to the discovery that
PG produced by Serratia marcescens 2170 triggered
apoptosis in several cancer cell lines but had no marked
toxicity in non-malignant cell lines (Montaner et al.,
2000; Díaz-Ruíz et al., 2001; Montaner and Pérez-
Tomás, 2001). Songia et al. (1997) and Mortellaro et al.
(1999) suggested that cell cycle-related proteins such as
retinoblastoma (Rb) and cyclin-dependent kinase-2 and 
-4 (cdk-2 and cdk-4) are the target molecules of UP and
PNU-156804 (a synthetic analogue of UP) to induce
growth arrest in G1 phase in human T and B
lymphocytes. However, Kawauchi et al. (1997) and
Azuma et al. (2000) suggested that apoptosis is the
mechanism of action of cPrG•HCl to induce suppression
of T cell proliferation. cPrG•HCl inhibits proliferation
and induces apoptosis in liver carcinoma cell lines
(Yamamoto et al., 1999) and in human breast cancer cell
lines (Yamamoto et al., 2000a), and also induces
differentiation in the human promyelocytic leukaemia
cell line HL60 (Yamamoto et al., 2000b). 
In this study, we examine for the first time the
relationship between cell cycle-related proteins such as
Rb and cdk-2 and the efficient inhibition of Jurkat T cell
proliferation induced by PG. 
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Materials and methods
Cell lines and culture conditions
Acute human T cell leukaemia cells (Jurkat clone
E6-1) were cultured in RPMI 1640 medium (Biological
Industries, Beit Haemek, Israel), supplemented with
10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin
(all from GIBCO BRL, Paisley, UK), and 2 mM L-
glutamine (Sigma Chemicals Co, St Louis, MO, USA),
at 37 ºC, 5% CO2 in air.
Isolation and purification of PG
PG was isolated from a culture broth of S.
marcescens 2170 as described previously (Montaner et
al., 2000). Stock solutions were prepared in methanol
and concentrations were determined by UV-Vis in 95%
EtOH-HCl. 
Thymidine incorporation assays 
The effect of PG on cell proliferation was
determined in a concentration-dependent fashion.
Briefly, Jurkat cells were plated at 5x105 cells/ml and
untreated or treated with 12-64 ng/ml PG. After 2 h
incubation, cells were labelled with 4 µCi/ml of [3H]-
thymidine for a further hour in the continuous presence
of PG. Then, cells were washed twice with PBS and 1
ml of cold 5% TCA (Sigma) was added for 30 min at 4
ºC. Consequently, samples were washed twice with cold
PBS and with 100 % ethanol and dried at 37 ºC. Finally,
precipitates were treated with 0.7 ml of 300 mM NaOH
for 1 h at 4 ºC and 0.5 ml of each sample was neutralised
with 0.1 ml 1.5 M HCl and added at 5 ml of scintillation
liquid and the radioactivity was counted (Beckman
LS5000TA, USA).
Western blot analysis
After cells (5x105/ml) were treated with 12, 32 and
64 ng/ml of PG for 3 h, they were lysed with 85 mM
Tris pH 6.8, 2% SDS, 1 µg/ml aprotinin, 1 µg/ml
leupeptin and 0.1 mM PMSF. Protein extracts were
quantified using Pierce’s BCA Assay Kit. Then, 50 µg
were electrophoresed on 12% polyacrylamide gel and
transferred to Immobilon-P membrane (Millipore,
Bedford, MA, USA). Membranes were blocked in 5 %
dry milk diluted in TBS-T (50 mM Tris-HCl pH 7.5, 150
mM NaCl, 0.1% Tween-20), for 1 h and then incubated
overnight with rabbit polyclonal (rp) or mouse
monoclonal (mm) antiserum according to the
manufacturer's instructions: anti-Rb (Santa Cruz
Biotechnologies (SCB), CA, USA, ref. C-15 sc-50, rp,
diluted 1:200), anti-cdk2 (Upstate Biotechnology (UBI),
NY, USA, 06-505, rp, diluted 1:1000), anti-cdk4 (SCB,
C-22 sc-260, rp, diluted 1:1000), anti-p21 (SCB, C-19
sc-397, rp, diluted 1:200), anti-p27 (UBI, 06-445, rp,
diluted 1:3000), anti-cyclin A (SCB, C-19 sc-596, rp,
diluted 1:5000), and anti-cyclin E antibody (SCB, HE12
sc-247, mm, diluted 1:400). Secondary antibodies
conjugated to HRP were goat anti-rabbit IgG (BioRad,
UK, ref. 170-6515) or goat anti-mouse (BioRad, ref.
170-6516), diluted 1:1000 in 5 % dry-milk-TBS-T, for 1
h at RT. Peroxidase was developed by incubating the
membrane with 2.25 mM luminol (Sigma) and 0.45 mM
p-iodophenol (Fluka, Buchs, Switzerland) in 50 mM
Tris-HCl pH 9.0 plus 0.03 % H2O2 for 1 min at RT and
enhanced chemiluminescence in an autoradiography
film.
Protein expression on Western images were
quantified using the image analysis software program
Phoretix 1-D advanced. Results are presented as % of
control (relative to the densitometry values).
Immunoprecipitation and kinase assays
To measure cdk2 activity, cells untreated or treated
with 32 and 64 ng/ml of PG were lysed in IP buffer (50
mM Tris-HCl pH 7.4, 5 mM EDTA, 250 mM NaCl, 50
mM NaF, 0.1% Triton X-100, 1 µg/ml aprotinin and 0.1
mM PMSF). Lysates (100 µg) were immunoprecipitated
with a normal rabbit serum (NRS), anti-cdk2, anti-cyclin
A or anti-cyclin E antibodies (UBI, ref. 06-138 and 06-
459, respectively). The immunoprecipitated complexes
were washed in kinase buffer (25 mM HEPES-Na pH
7.4, 5 mM MgCl2, 0.5 mM dithiothreitol) and then
incubated in kinase buffer containing 1 mM ATP, 3 µg of
histone H1, and 10 µCi of [32P]ATP for 30 min at 30 ºC
in a final volume of 50 µl. The samples were
electrophoresed, and gels were stained with Coomassie
Blue, dried, and exposed to X-ray films at -80 ºC. 
Statistical analysis
All data points shown are mean value ± s.e.m. of
three independent experiments. Statistical significance of
differences was assessed by ANOVA (Fisher's PLSD
test). Differences between untreated and treated cells
with PG are indicated by *P<0.05; **P<0.01;
***P<0.001.
Hoechst staining
Cells were stained with the intercalating DNA dye
Hoechst 33342 (Sigma) to reveal their nuclear
morphology. Jurkat cells (5x105/ml) were incubated in
the absence (control cells) or in the presence of 64 ng/ml
of PG for 3 h. Cells were then washed in PBS and
resuspended in PBS plus Hoechst 33342 to a final
concentration of 2 µg/ml and incubated for 30 min at
37ºC in the dark. After incubation, cells were washed in
PBS and the sections were examined fluorometrically
(emission above 420 nm, excitation 330-385 nm) with a
Leitz Diaplan microscope and photographed with a Wild
MPS 45 Photoautomat system.
Analysis of DNA fragmentation
DNA fragmentation was analysed by agarose gel
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electrophoresis, as described previously (Montaner et al.,
2000). Briefly, 1x106 cells per ml were untreated
(control) or treated (12-64 ng/ml of PG) for 3 h, then
washed in PBS and resuspended in ice-cold lysis buffer
(10 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.2% Triton X-
100). After incubating for 15 min at 4 ºC, cell lysates
were centrifuged at 14,000 X g for 15 min and the
supernatant was treated with 0.2 mg/ml of proteinase K
in a buffer containing 150 mM NaCl, 10 mM Tris-HCl
pH 8.0, 40 mM EDTA and 1% SDS, for 4 h at 37 ºC.
The DNA preparations were phenol/chloroform
extracted twice to remove proteins. DNA was
precipitated with 140 mM NaCl and two volumes of
ethanol at -20ºC overnight. DNA precipitates were
recovered by centrifugation at 14,000xg for 10 min at 4
ºC, washed twice in cool 70% ethanol and air dried.
DNA pellets were resupended in 15 ml of TE (10 mM
Tris-HCl pH 8.0, 1 mM EDTA) and treated with DNase-
free RNase (Boehringer Mannheim, Mannheim,
Germany) for 1 h at 37 ºC. 3.2 ml of loading buffer was
added to each tube and the DNA preparations were
electrophoresed in 1% agarose gels which contained
ethidium bromide. Gels were placed on an UV light box
to visualize the DNA ladder pattern.
Results
Since PG had been shown to induce apoptosis in
haematopoietic cancer cell lines (Montaner et al., 2000),
we determined the effects of PG on Jurkat cell line
proliferation in a dose-response study. As shown in
Figure 1, PG at the dose 64 ng/ml inhibits the uptake of
[3H]-thymidine by about 70%.
We analysed the induction of several cyclins and
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Fig. 1. PG inhibits the proliferation of Jurkat cells in a concentration-
dependent fashion. In the thymidine incorporation assay, cells are
untreated (control) or treated with 12, 32 or 64 ng/ml PG for 3 h. Data
are mean values obtained from three independent experiments.
Statistical significance of differences between untreated cells and cells
treated with PG at different doses are assayed by ANOVA. Fishers
PLSD are indicated by *P<0.05 and ***P<0.001.
Fig. 2. Effect of PG on cell cycle-related proteins in a dose-response study. A. Jurkat cells are untreated (control) or treated with 12, 32 or 64 ng/ml PG
for 3 h. Equal amounts of whole cell lysate (50 µg) are subjected to electrophoresis and analysed by Western blotting for the presence of cyclin A,
cyclin E, cdk2, and cdk4. B. Effect of PG on cdk2 activity. Jurkat cells are untreated (control) or treated with 32 and 64 ng/ml PG for 3 h. Then, extracts
of these cells are immunoprecipitated with anti-cyclin A, anti-cyclin E antibodies or a NRS and analysed by Western blot using phospho-cdk2
antibodies. C. Jurkat cells are untreated (control) or treated with 12, 32 or 64 ng/ml PG for 3 h, then, 50 µg of whole cell lysate are subjected to
electrophoresis and analysed by Western blotting for the presence of  p27 and p21.
cdks involved in G1 progression and G1-S transition.
The analysis was at the protein level by Western blot.
Total cell extracts from an equivalent number of cells
were loaded in each lane. That equal amounts of protein
were loaded per lane was verified by Ponceau red
staining of the unused part of the blot (data not shown). 
We performed dose-response experiments in order to
demonstrate that the inhibition of expression of these
molecules paralleled the inhibition of proliferation (Fig.
1). PG inhibited cyclin E protein expression, with an
IC50 of 40 ng/ml but had no effect on cyclin A (Fig. 2A).
The expression of cdk2 and cdk4 was also analysed and
only cdk2 was seen significantly inhibited in its
expression by PG, with an IC50 of 62 ng/ml (Fig. 2A).
To verify that PG indeed inhibited the kinase activity of
cdk2, a kinase assay was performed on cdk2
immunoprecipitates, with histone H1 as substrate. As
shown in Fig. 2B, PG almost totally abolished both the
cyclin A-cdk2- and the cyclin E-cdk2-dependent kinase
activity, with an IC50 of 62 ng/ml and 27 ng/ml,
respectively.
Cell cycle progression in T cells is also regulated by
cdk inhibitors (ckI). In particular, the ckI p27 and p21
are known to be expressed in T cells. We therefore
analysed the effect of PG on p27 and p21 expression. As
shown in Fig. 2C, PG completely abolished the
expression of p27 protein at the concentration of 64
ng/ml (IC50: 42 µg/ml). Finally, the Jurkat cell(following PMA stimulation) was accompanied by the
induction of p21. This induction was almost completely
abolished by PG (IC50: 31 ng/ml) (Fig.2C).
Therefore, we went on to investigate the effect of PG
on Rb phosphorylation. As shown in Figure 3A, Rb
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Fig. 4. PG induces
apoptosis in Jurkat
cells. A. Fluorescence
microscopic analysis
of Jurkat nuclei with
Hoechst 33342
staining. Cells are
untreated (-
Prodigiosin) or treated
(+ Prodigiosin) with 64
ng/ml PG for 3 h. PG-
treated cells show
apoptotic signs with
chromatin
condensation and
nuclei fragmentation.
B. DNA fragmentation
induced by PG is
observed in the
agarose gel
electrophoresis. For
this assay, the cells
are untreated (control)
or treated with 12-64
ng/ml PG for 3 h.
Fig. 3. Effect of PG on retinoblastoma. A. Western blot analysis of
phosphorylated Rb protein from Jurkat cells untreated (control) or
treated with 12, 32 or 64 ng/ml PG for 3 h. 50 µg of whole cell protein
extracts are subjected to electrophoresis. In all cases, a representative
study is shown; two additional experiments yielded similar results. B.
Quantification of Rb immunoreactive bands intensity. The densitometric
analysis of the hyperphosphorylated (ppRb) and hypophosphorylated
(pRb) forms of Rb is performed. Bands densitometry is presented as the
% of control. Statistical significance of differences between untreated
cells and cells treated with PG at different doses are assayed by
ANOVA, Fishers PLSD are indicated by *P<0.05 and ***P<0.001.
hyperphosphorylation was evident in untreated Jurkat
cells and was partially, although not completely,
inhibited by PG. A densitometric analysis was done
using the "Phoretix-1D gel analysis software" showing
underphosphorylation of the hyperphosphorylated Rb
protein (Fig 3B).
All the data demonstrated that PG strongly inhibits
the expression of cyclin E, cdk2, p27 and p21, the
induction of cyclin A-cdk2 and cyclin E-cdk2 kinase
activity, and the phosphorylation of Rb. 
In order to determine that PG had an apoptotic effect
at these conditions, Jurkat cells were treated with graded
doses of PG for 3h. Apoptosis was determined by
nuclear condensation (Fig. 4A) and typical DNA
fragmentation (Fig. 4B), which indicated that the
suppression of T cell proliferation was a result of
apoptotic cell death.
Discussion
New drugs associated with apoptotic cell death that
are expected to be effective against high-proliferation
tumours like leukaemia are being screened for new
anticancer drug treatment (Cameron and Feuer, 2000).
PG, UP and cPrG⋅HCl, three members of the prodigiosin
family, were found to have interesting immuno-
suppressive properties (Tsuji et al., 1992; Songia et al.,
1997; Han et al., 1998; Mortellaro et al., 1999) and
apoptotic effects on cancer cell lines (Kawauchi et al.,
1997; Azuma et al., 2000; Lee et al., 2000; Montaner et
al., 2000; Yamamoto et al., 2000a; Díaz-Ruíz et al.,
2001; Montaner and Pérez-Tomás, 2001, 2002a,b) and
on hepatocellular carcinoma xenografts (Yamamoto et
al., 1999). Along these lines, UP and PNU-156804, a
new analogue of UP, inhibit equally well both T and B
lymphocyte proliferation, but not transformed leukaemic
Jurkat cells (Songia et al., 1997; Mortellaro et al., 1999).
However, cPrG•HCl suppresses Jurkat proliferation as a
result of apoptotic cell death (Kawauchi et al., 1997). In
view of these contradictory results we extended our
study in order to elucidate the mechanism of action of
PG on the proliferation of the human T cell-derived
Jurkat cell line.
PG at 64 ng/ml inhibited the uptake of [3H]-
thymidine by about 70 % (Fig. 1), whereas it decreased
Jurkat cell viability by only 30% (Montaner et al., 2000).
Nevertheless, 50 ng/ml UP did not affect Jurkat cell
growth for 2 days. The percentage inhibition of
thymidine uptake paralleled the percentage increase in
cell death only at 4- to 6-fold higher concentrations,
suggesting that UP is toxic to cells at these
concentrations (Songia et al., 1997). The differences in
the chemical structures of the A-pyrrole rings between
PG and UP plays a key role in the cytotoxic potency
(Melvin et al., 2000), and it is tempting to speculate that
they are responsible for these different effects. 
The fact that PG blocked cell proliferation suggested
that some general cell cycle-associated proteins required
for G0-G1-S phase transitions could be a target of PG
action. We demonstrated that PG abolished cyclin E
protein expression, but had no effect on cyclin A.
However, drugs that also prevent mitogen-induced G1-S
progression, like doxazosin, inhibit cyclin A expression
(Kintscher et al., 2000). PG almost totally abolished both
the cyclin A-cdk2- and the cyclin E-cdk2-dependent
kinase activity.
Interestingly, the resistance of cancer to
chemotherapy may be due in part to the high frequency
of mutation in p53 that impairs p53-dependent apoptosis.
Many anticancer agents such as doxorubicine, etoposide
or 5-fluorouracil induce apoptosis via the p53-dependent
pathway (Lowe et al., 1993). Thus, identifying
chemotherapeutic agents like PG that act independently
of the p53 pathway (Montaner et al., 2000) is of major
importance and could lead to such agents having an edge
over other chemotherapeutic drugs.
Cell cycle progression in T cells is also regulated by
cdk inhibitors (ckI). In particular, the ckI p27 and p21,
both of which are p53-inducible genes that work to
block the transition of the cell from G1 to S, are known
to be expressed in T cells. PG abolished the expression
of p27 protein and in PMA stimulated Jurkat cells, the
induction of p21 was also abolished by PG. Thus, the
conventional view is that the role of p27 determines the
proliferative threshold to mitogenic growth factors.
However cells under stress, in states such as growth
factor deprivation, have lower or no p27 protein levels
and they exit the cell cycle and undergo apoptosis
(Hiromura et al., 1999). It has also been shown that
p21Cip1,Waf1 and p27 are cleaved during growth factor
deprivation-induced apoptosis in endothelial cells
(Levkau et al., 1998). Our results support a different
perspective on the biological function of p27 and suggest
that p27, in the presence of PG, coordinates the final
outcome of proliferation or death of the cell. 
We show that PG, like UP and PNU-156804 (Songia
et al., 1997; Mortellaro et al., 1999), induces a p27
protein decrease and inhibits cyclin A-cdk2 and cyclin
E-cdk2 kinase activity. Cyclins E and A in association
with cdk2 serve as positive regulators for mammalian
cell cycle progression through the G1-S transition and
subsequent cell proliferation. However, Hiromura et al.
(1999) showed that in serum-starved p27-/- cells cyclin
E-cdk2 activity decreased, while cyclin A-cdk2 activity
increased. Mgbonyebi et al. (1999) suggest that cyclin-
kinase inhibitors like roscovitine induces apoptosis and
may be involved in cytoskeletal regulation by reducing
the polymerisation of actin microfilaments. These
findings are consistent with the results shown here and,
together with the fact that PG causes the reorganisation
of actin cytoskeleton and may promote the breakdown of
actin microfilaments (Díaz-Ruíz et al., 2001), they
indicate that PG follows the same mechanism as
roscovitine. 
Furthermore, PG inhibited Rb phosphorylation This
result is in concordance with the findings shown above,
since proteins like cyclins, cdks and Rb itself can check
cell cycle progression, and hold cells in quiescence or
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even lead cells to commit suicide.
Recent studies have shown that PG interact with
DNA and uncoil the double-stranded helix (Melvin et
al., 2000). Furthermore, we have demonstrated that PG
binds directly to DNA by intercalation and that it
cleavages the double-strand DNA, inhibiting the
topoisomerase I enzyme (manuscript in preparation).
These findings may explain the effect of PG in cell
cycle-related proteins that we have shown here.
In summary, this study shows that prodigiosin family
members form a new group of molecules with a
common mechanism of action inducing G1-S transition
arrest in association with the down-regulation of the
expression of cyclin E, cdk2, p27 and p21, induction of
the cyclin A-cdk2 and cyclin E-cdk2 kinase activity, and
the phosphorylation of Rb. Further studies of PG activity
in primary tumours and the characterisation of the PG
internalisation pathway are now underway in our
laboratory. 
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